Novartis Lamisil, Janssen Sporanox Liver Toxicity Warning Added To Labeling
Executive Summary
Novartis Lamisil patients should be assessed for pre-existing liver disease before receiving the antifungal tablets, revised labeling recommends.
You may also be interested in...
Watson Ferrlecit Cancer Study With Epoetin Will Enter Phase II By Year-End
Watson Pharmaceuticals plans to initiate a Phase II trial of Ferrlecit for cancer patients by the year-end.
Watson Ferrlecit Cancer Study With Epoetin Will Enter Phase II By Year-End
Watson Pharmaceuticals plans to initiate a Phase II trial of Ferrlecit for cancer patients by the year-end.
Aslera Approval May Be Delayed, Watson Says; Sales Projections Adjusted
Watson expects FDA approval for its lupus treatment Aslera may be delayed following an indecisive advisory committee meeting in April, the company told investors during a May 7 conference call.